Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 19c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q4 EPS of ($0.09), $0.19 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $71.3 million versus the consensus estimate of $54.72 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• FDA approves Revolution Medicines pancreatic cancer drug Rasonque
• J. M. Smucker (SJM) Tops Q1 EPS by 103c
• JinkoSolar (JKS) Misses Q2 EPS by RMB 7.10, Misses on Revenue